TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22989898

Group type: EXPERIMENTAL
Intervention: Intensive SBP reduction (to <=140mmHg) using intravenous nicardipine infusion for 24 hours post-randomization
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Standard SBP reduction (to 140-180mmHg)
Number of subjects: 1280
Study: 20171656

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 18021872

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily for 4 weeks, followed by 45 mg daily for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 16040446

Group type: EXPERIMENTAL
Intervention: High-dose xylitol (HX; 6.0 g xylitol)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-dose xylitol (LX; 2.0 g xylitol)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (CTR; no xylitol)
Number of subjects: 11
Study: 11846205

Group type: EXPERIMENTAL
Intervention: Bioactive glass (BG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unfilled control (C)
Number of subjects: 30
Study: 12296423

Group type: EXPERIMENTAL
Intervention: Trained hypokinetic subjects (THKS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Untrained hypokinetic subjects (UHKS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trained ambulatory control subjects (TACS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untrained ambulatory control subjects (UACS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison between THKS and UHKS
Number of subjects: 40
Study: 9839589

Group type: EXPERIMENTAL
Intervention: p53 autoantibodies positive patients (13 patients with cancer)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (1 patient with benign disease)
Number of subjects: 198
Study: 8009976

Group type: EXPERIMENTAL
Intervention: Interferon-beta (2 x 10(6) I.U. daily) for ten days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (2 ml of saline solution daily) for ten days
Number of subjects: 37
Study: 2782336

Group type: EXPERIMENTAL
Intervention: Group I: Clindamycin and tobramycin for >= 24 hours
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Group II: Clindamycin and tobramycin for >= 48 hours
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Group III: Clindamycin and tobramycin for >= 48 hours followed by 7-day course of oral Augmentin
Number of subjects: 109
Study: 991009

Group type: EXPERIMENTAL
Intervention: Home care after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital care after surgery
Number of subjects: 0
Study: 7031859

Group type: EXPERIMENTAL
Intervention: 40% idoxuridine (IDU) dissolved in dimethyl sulphoxide (DMSO)
Number of subjects: 122

Group type: COMPARATOR
Intervention: DMSO and saline flavoured with garlic (Control)
Number of subjects: 122
Study: 31350526

Group type: EXPERIMENTAL
Intervention: Veliparib plus FOLFIRI±bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI±bevacizumab
Number of subjects: 0
Study: 29300197

Group type: EXPERIMENTAL
Intervention: Sucrose solution (25%; 0.5 mL/kg) administered 2 minutes before procedures
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 104
Study: 27611054

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 75
Study: 25357253

Group type: EXPERIMENTAL
Intervention: Proxy high-EE speech sample
Number of subjects: 38

Group type: COMPARATOR
Intervention: Neutral speech samples
Number of subjects: 38
Study: 22622278

Group type: EXPERIMENTAL
Intervention: EMDR treatment with one-week sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline (SSRI) treatment
Number of subjects: 0
Study: 20195553

Group type: EXPERIMENTAL
Intervention: Patient-controlled oral analgesia (PCOA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: RN-administered short-acting oral opioids
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PCOA
Number of subjects: 88

Group type: COMPARATOR
Intervention: RN administration
Number of subjects: 88
Study: 18805154

Group type: EXPERIMENTAL
Intervention: Processed shed blood (treated)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Unprocessed shed blood (control)
Number of subjects: 266
Study: 15956047

Group type: EXPERIMENTAL
Intervention: Iron medicine (ferrous gluconate at 3 mg/kg of elemental iron once daily)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Iron fortified follow-on milk (12 mg/l ferrous iron)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Iron fortified partially modified cows' milk (12.9 mg/l ferrous iron)
Number of subjects: 234
Study: 12095498

Group type: EXPERIMENTAL
Intervention: 100 mg of clomiphene citrate (CC) on days 1-5
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo on days 1-5
Number of subjects: 33
Study: 11503828

Group type: EXPERIMENTAL
Intervention: Etidronic acid (disodium etidronate)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 8707127

Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus propranolol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 200
Study: 1922235

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg (oral)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Cefixime 800 mg (oral)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg (intramuscular)
Number of subjects: 333
Study: 6981167

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) - 160 mg of TMP plus 800 mg of SMZ, two double-strength tablets twice daily for two days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ampicillin plus probenecid - 3.5 g of ampicillin plus 1 g of probenecid, single dose
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ampicillin plus probenecid
Number of subjects: 69
Study: 30819688

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (BVB) 1.25 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA) 4 mg
Number of subjects: 58
Study: 29402270

Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment group
Number of subjects: 274

Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 274
Study: 27621258

Group type: EXPERIMENTAL
Intervention: Self-help cognitive behaviour therapy (CBT) intervention lasting 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment-wait control condition (NTWC)
Number of subjects: 100
Study: 24899268

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intensive lifestyle weight loss intervention (LWLI)
Number of subjects: 69
Study: 22105940

Group type: EXPERIMENTAL
Intervention: Dual axis rotational coronary angiography (DARA)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Conventional single and biplane coronary imaging
Number of subjects: 463
Study: 20197013

Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir 1,000/100 mg twice daily for 2 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (baseline digoxin dose of 0.5 mg)
Number of subjects: 17
Study: 17437688

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs); specific dosage and duration not available
Number of subjects: 0
Study: 15560958

Group type: EXPERIMENTAL
Intervention: 100 mg/day clozapine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 300 mg/day clozapine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 600 mg/day clozapine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 100 mg/day clozapine (heavy smokers)
Number of subjects: 47
Study: 12930926

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) given concurrently with chemotherapy
Number of subjects: 640

Group type: COMPARATOR
Intervention: No G-CSF
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) in standard-risk AML
Number of subjects: 640

Group type: COMPARATOR
Intervention: No G-CSF in standard-risk AML
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) in unfavorable prognosis subgroup
Number of subjects: 640
Study: 10519559

Group type: EXPERIMENTAL
Intervention: Flexion‐distraction technique (active treatment)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham adjustments (placebo treatment)
Number of subjects: 18
Study: 7856781

Group type: EXPERIMENTAL
Intervention: Low-intensity interventions integrated into routine prenatal care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 0
Study: 2391397

Group type: EXPERIMENTAL
Intervention: Acetaminophen sustained release (SR) high dose (2000 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Acetaminophen immediate plus sustained release (IR + SR) high dose (500 + 1500 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Acetaminophen standard tablet high dose (1000 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Acetaminophen standard tablet low dose (500 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Acetaminophen sustained release (SR) low dose (1000 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Acetaminophen immediate plus sustained release (IR + SR) low dose (250 + 750 mg)
Number of subjects: 200
Study: 7002705

Group type: EXPERIMENTAL
Intervention: Caffeinated instant coffee at pH 4.5
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeinated instant coffee at pH 7.0
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeinated instant coffee at pH 4.5 with mixed nutrient test meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeinated instant coffee at pH 7.0 with mixed nutrient test meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeinated instant coffee at neutral pH with mixed nutrient test meal
Number of subjects: 36
Study: 29357777

Group type: EXPERIMENTAL
Intervention: Acute poisoning patients
Number of subjects: 277

Group type: COMPARATOR
Intervention: Control patients (nonpoisoned)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Toxic alcohols
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 277
Study: 29579015

Group type: EXPERIMENTAL
Intervention: aVOR app
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (traditional practice)
Number of subjects: 113
Study: 26253255

Group type: EXPERIMENTAL
Intervention: cediranib
Number of subjects: 29
Study: 24552803

Group type: EXPERIMENTAL
Intervention: Personal oxygen supplement (OS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (compressed air)
Number of subjects: 20
Study: 22713287

Group type: COMPARATOR
Intervention: Cinaciguat (50, 100, and 150 µg/h) in COMPOSE 1
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cinaciguat (not specified dosage) in COMPOSE EARLY
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cinaciguat (10 and 25 µg/h) in COMPOSE 2
Number of subjects: 74
Study: 20439630

Group type: EXPERIMENTAL
Intervention: t(8;21)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: inv(16)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: t(15;17)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: t(8;21) with additional aberrations apart from del(9q) or -X/-Y
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Complex karyotype
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Monosomy 7
Number of subjects: 454

Group type: COMPARATOR
Intervention: Remaining patients with cytogenetic data
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: MLL rearrangement
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: t(9;11) with additional aberrations
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: MLL rearrangements other than t(9;11) and t(11;19)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Aberrations in 12p
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Aberrations of chromosome 5
Number of subjects: 454
Study: 17913322

Group type: EXPERIMENTAL
Intervention: Lithium administration for two weeks
Number of subjects: 8
Study: 16002915

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol 2.5 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol 5 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Maximal bronchodilation (Emax) FEV(1)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Emax PEFR
Number of subjects: 86
Study: 11985738

Group type: EXPERIMENTAL
Intervention: Intervention group (specific interventions not detailed)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Eligible but did not participate
Number of subjects: 616
Study: 10070817

Group type: EXPERIMENTAL
Intervention: Reduction of fibrinogen in patients with high baseline fibrinogen levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline fibrinogen levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction of fibrinogen
Number of subjects: 0
Study: 7673546

Group type: EXPERIMENTAL
Intervention: Short‐Term Dynamic Psychotherapy (STDP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief Adaptive Psychotherapy (BAP)
Number of subjects: 0
Study: 1710624

Group type: EXPERIMENTAL
Intervention: 24 IU GH administered intramuscularly on alternate days starting on cycle day 4
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (sterile saline) administered intramuscularly on alternate days starting on cycle day 4
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 24 IU GH administered intramuscularly
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 16
Study: 6798616

Group type: COMPARATOR
Intervention: Alprazolam (0.25, 0.5, and 1.0 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diazepam (2, 5, and 10 mg)
Number of subjects: 16
Study: 31994365

Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg)/Naloxone (5 mg) for the first 48 hours
Number of subjects: 83

Group type: COMPARATOR
Intervention: Morphine (0.2-0.4 mg/kg/day)
Number of subjects: 83
Study: 31422852

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 104
Study: 29862734

Group type: EXPERIMENTAL
Intervention: Kerr resin filler
Number of subjects: 126

Group type: COMPARATOR
Intervention: Ordinary resin filler
Number of subjects: 126
Study: 25373836

Group type: EXPERIMENTAL
Intervention: Patient requests for diagnostic tests
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Patient requests for pain medications
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Patient requests for specialist referrals
Number of subjects: 824
Study: 23542809

Group type: COMPARATOR
Intervention: Mild cognitive impairment (MCI) patients during immediate recall of sequences of 5 items.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mild cognitive impairment (MCI) patients during delayed recall.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) patients immediate recall performance.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) patients delayed recall performance.
Number of subjects: 32
Study: 20714166

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride exposure
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (not exposed to sevelamer hydrochloride)
Number of subjects: 175
Study: 19320662

Group type: EXPERIMENTAL
Intervention: Vildagliptin plus high-dose metformin combination therapy (50 mg + 1000 mg twice daily)
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Vildagliptin plus low-dose metformin combination therapy (50 mg + 500 mg twice daily)
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Vildagliptin monotherapy (50 mg twice daily)
Number of subjects: 1179

Group type: COMPARATOR
Intervention: High-dose metformin monotherapy (1000 mg twice daily)
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Vildagliptin plus high-dose metformin combination therapy
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Vildagliptin plus low-dose metformin combination therapy
Number of subjects: 1179
Study: 16679331

Group type: EXPERIMENTAL
Intervention: Family style mealtimes
Number of subjects: 178

Group type: COMPARATOR
Intervention: Usual individual pre‐plated service
Number of subjects: 178
Study: 15561658

Group type: EXPERIMENTAL
Intervention: Tub bathing
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sponge bathing
Number of subjects: 102
Study: 11411817

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-50 mg/day)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 9103727

Group type: EXPERIMENTAL
Intervention: PD symptom levels
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: PD diagnoses
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Change in PD symptom levels
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Progression of HIV infection
Number of subjects: 118
Study: 8021335

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (M-5041T), 6 mg applied for 3 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral clonidine (Catapres), 0.075 mg every 12 hours for 3 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (M-5041T)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral clonidine (Catapres)
Number of subjects: 8
Study: 2739347

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no preoperative chemotherapy)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 31472393

Group type: EXPERIMENTAL
Intervention: Clear glasses (no filter)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Orange glasses (filtering blue wavelength)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: White light
Number of subjects: 35

Group type: COMPARATOR
Intervention: Orange light
Number of subjects: 35
Study: 25175313

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 329

Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Sensor use
Number of subjects: 329
Study: 23999956

Group type: EXPERIMENTAL
Intervention: 6-session intervention including trauma-focused treatments (psychoeducation, cognitive restructuring, progressive muscle relaxation, development of trauma narrative) and infant redefinition
Number of subjects: 105

Group type: COMPARATOR
Intervention: Active comparison group
Number of subjects: 105
Study: 20615632

Group type: EXPERIMENTAL
Intervention: Ultrahigh PSA levels (≥50 ng/ml)
Number of subjects: 2193

Group type: EXPERIMENTAL
Intervention: Gleason grades of 8 to 10
Number of subjects: 2193
Study: 18234129

Group type: EXPERIMENTAL
Intervention: 6-week exercise intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary restraint
Number of subjects: 0
Study: 16765182

Group type: EXPERIMENTAL
Intervention: Intravesical BCG therapy
Number of subjects: 4767

Group type: COMPARATOR
Intervention: No BCG treatment (control group)
Number of subjects: 4767

Group type: EXPERIMENTAL
Intervention: BCG therapy with maintenance treatment
Number of subjects: 4767

Group type: EXPERIMENTAL
Intervention: BCG therapy for papillary carcinoma
Number of subjects: 4767

Group type: EXPERIMENTAL
Intervention: BCG plus chemotherapy/immunotherapy
Number of subjects: 4767
Study: 12966127

Group type: EXPERIMENTAL
Intervention: Apheresis for multiple sclerosis
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Apheresis for thrombotic thrombocytopenic purpura
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Apheresis for myeloma cast nephropathy
Number of subjects: 177
Study: 10880791

Group type: EXPERIMENTAL
Intervention: Externally-triggered (ET) task
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Self-initiated (SI) task
Number of subjects: 7
Study: 9552503

Group type: EXPERIMENTAL
Intervention: Excimer laser angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saline infusion during excimer laser angioplasty
Number of subjects: 0
Study: 1712282

Group type: EXPERIMENTAL
Intervention: Deviant stimuli (650 Hz, 70 dB, 20 msec)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Deviant stimuli (standard 600 Hz, 80 dB SPL, 50 msec)
Number of subjects: 10
Study: 6840946

Group type: EXPERIMENTAL
Intervention: 2% miconazole nitrate
Number of subjects: 15

Group type: COMPARATOR
Intervention: 2.5% selenium disulfide
Number of subjects: 15
Study: 31479530

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri lozenges, used twice-daily for 28 days as an adjunct to NSPT
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo lozenges, used twice-daily for 28 days as an adjunct to NSPT
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri lozenges
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 59
Study: 28222678

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg (Group D1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg/kg (Group D2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intravenous saline (Group D0)
Number of subjects: 75
Study: 26890472

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 2502
Study: 24518533

Group type: EXPERIMENTAL
Intervention: Exercise program (12-week period, 3 times per week)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study: 23059960

Group type: EXPERIMENTAL
Intervention: Tilt at ≥15°
Number of subjects: 157

Group type: COMPARATOR
Intervention: Tilt at <15°
Number of subjects: 157

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 157
Study: 19547873

Group type: EXPERIMENTAL
Intervention: Isoniazid chemoprophylaxis (300 mg/day) for six months
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Isoniazid chemoprophylaxis
Number of subjects: 138
Study: 16787996

Group type: EXPERIMENTAL
Intervention: Bias-adjusted parameter estimator for the treatment coefficient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Point estimator for treatment effect
Number of subjects: 0